194 related articles for article (PubMed ID: 37047086)
21. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis.
Luan L; Han S; Wang H; Liu X
Int Immunopharmacol; 2015 Dec; 29(2):278-284. PubMed ID: 26585971
[TBL] [Abstract][Full Text] [Related]
22. TNF-α inhibitors reduce the pathological Th
Campanati A; Orciani M; Lazzarini R; Ganzetti G; Consales V; Sorgentoni G; Di Primio R; Offidani A
Exp Dermatol; 2017 Apr; 26(4):319-324. PubMed ID: 27376466
[TBL] [Abstract][Full Text] [Related]
23. Long-term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study.
Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
Dermatol Ther; 2020 Nov; 33(6):e14110. PubMed ID: 32734665
[TBL] [Abstract][Full Text] [Related]
24. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
25. Severity of periodontitis and salivary interleukin-1β are associated with psoriasis involvement.
Wu KJ; Tu CC; Hu JX; Chu PH; Ma KS; Chiu HY; Kuo MY; Tsai TF; Chen YW
J Formos Med Assoc; 2022 Oct; 121(10):1908-1916. PubMed ID: 35105497
[TBL] [Abstract][Full Text] [Related]
26. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
[TBL] [Abstract][Full Text] [Related]
27. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
28. Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study.
Eng GP; Bouchelouche P; Bartels EM; Bliddal H; Bendtzen K; Stoltenberg M
PLoS One; 2016; 11(9):e0162316. PubMed ID: 27606615
[TBL] [Abstract][Full Text] [Related]
29. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
Asahina A; Umezawa Y; Yanaba K; Nakagawa H
J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
[TBL] [Abstract][Full Text] [Related]
30. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
31. Biologics in the treatment of pustular psoriasis.
Wang WM; Jin HZ
Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
[TBL] [Abstract][Full Text] [Related]
32. The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity.
Wu LT; Qiao ZH; Tian JB; Lin JL; Hou SC; Liu XM
Skin Res Technol; 2023 Jul; 29(7):e13405. PubMed ID: 37522491
[TBL] [Abstract][Full Text] [Related]
33. Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Andres-Ejarque R; Ale HB; Grys K; Tosi I; Solanky S; Ainali C; Catak Z; Sreeneebus H; Saklatvala J; Dand N; de Rinaldis E; Chapman A; Nestle FO; Barnes MR; Warren RB; Reynolds NJ; Griffiths CEM; Barker JN; Smith CH; Di Meglio P;
Nat Commun; 2021 Aug; 12(1):4741. PubMed ID: 34362923
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis.
Hagino T; Saeki H; Kanda N
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769622
[TBL] [Abstract][Full Text] [Related]
35. Genetic prediction of the effectiveness of biologics for psoriasis treatment.
Nishikawa R; Nagai H; Bito T; Ikeda T; Horikawa T; Adachi A; Matsubara T; Nishigori C
J Dermatol; 2016 Nov; 43(11):1273-1277. PubMed ID: 27129929
[TBL] [Abstract][Full Text] [Related]
36. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
37. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
38. Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections.
Bruno M; Davidson L; Koenen HJPM; van den Reek JMPA; van Cranenbroek B; de Jong EMGJ; van de Veerdonk FL; Kullberg BJ; Netea MG
J Invest Dermatol; 2022 Nov; 142(11):2929-2939.e8. PubMed ID: 35662644
[TBL] [Abstract][Full Text] [Related]
39. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.
Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
J Dermatol; 2017 Apr; 44(4):363-369. PubMed ID: 27774694
[TBL] [Abstract][Full Text] [Related]
40. Measurement of pre-treatment inflammatory cytokine levels is valuable for prediction of treatment efficacy to tumor necrosis factor inhibitor in axial spondyloarthritis patients.
Peng F; Chen F; Wen H; Bai J; Tian Y
Int J Rheum Dis; 2022 Aug; 25(8):844-850. PubMed ID: 35694730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
